Loading...
Market
What will be the market share of Lecanemab in the UK Alzheimer's treatment market by December 31, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market share reports from healthcare market analysis firms
Story
Alzheimer's Wonder Drug Lecanemab, Biggest Breakthrough in Decades, Set for UK Approval
Aug 21, 2024, 11:46 PM
The Alzheimer's wonder drug Lecanemab is set to receive approval for use in Britain, marking a significant advancement in the treatment of the disease. This drug is the first to demonstrate the ability to slow down the progression of Alzheimer's, offering new hope to patients and healthcare providers. The approval is expected to allow Lecanemab to be prescribed privately, with potential for future availability through the National Health Service (NHS). The Medicines and Healthcare products Regulatory Agency (MHRA) is anticipated to make a favorable decision soon. While not a cure, Lecanemab represents a crucial step forward in Alzheimer's treatment, highlighting the need for increased investment in dementia services and early diagnosis. Described as the biggest breakthrough in decades, this development underscores the importance of continued research and support for Alzheimer's patients.
View original story
Similar markets
Less than 500 • 25%
500 to 1000 • 25%
1001 to 2000 • 25%
More than 2000 • 25%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Kisunla > 50% • 25%
Kisunla 30-50% • 25%
Kisunla 10-30% • 25%
Kisunla < 10% • 25%
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
PrecivityAD2™ dominates (>50%) • 25%
Sunbird Bio dominates (>50%) • 25%
Both share equally (~50% each) • 25%
Other diagnostic tests dominate • 25%
Less than £1000 • 25%
£1000 to £2000 • 25%
£2001 to £3000 • 25%
More than £3000 • 25%
Kisunla™ > Leqembi • 25%
Leqembi > Kisunla™ • 25%
Kisunla™ and Leqembi have equal market share • 25%
Other treatments lead • 25%
